Incyte focuses on the discovery and development of small-molecule drugs... Show more
INCY saw its Momentum Indicator move below the 0 level on April 04, 2025. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 103 similar instances where the indicator turned negative. In of the 103 cases, the stock moved further down in the following days. The odds of a decline are at .
The 50-day moving average for INCY moved below the 200-day moving average on April 09, 2025. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where INCY declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for INCY entered a downward trend on April 17, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where INCY's RSI Indicator exited the oversold zone, of 37 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 61 cases where INCY's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for INCY just turned positive on April 15, 2025. Looking at past instances where INCY's MACD turned positive, the stock continued to rise in of 38 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where INCY advanced for three days, in of 297 cases, the price rose further within the following month. The odds of a continued upward trend are .
INCY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. INCY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.268) is normal, around the industry mean (13.444). INCY has a moderately high P/E Ratio (388.067) as compared to the industry average of (62.833). Projected Growth (PEG Ratio) (0.372) is also within normal values, averaging (1.754). Dividend Yield (0.000) settles around the average of (0.026) among similar stocks. P/S Ratio (2.889) is also within normal values, averaging (250.783).
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. INCY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
a developer of drugs
Industry Biotechnology
A.I.dvisor indicates that over the last year, INCY has been loosely correlated with REGN. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if INCY jumps, then REGN could also see price increases.
Ticker / NAME | Correlation To INCY | 1D Price Change % | ||
---|---|---|---|---|
INCY | 100% | +0.83% | ||
REGN - INCY | 39% Loosely correlated | +2.53% | ||
RPRX - INCY | 37% Loosely correlated | +1.27% | ||
KYMR - INCY | 35% Loosely correlated | +3.80% | ||
XENE - INCY | 34% Loosely correlated | +3.94% | ||
RCKT - INCY | 33% Loosely correlated | +2.93% | ||
More |